Alpheon
Interferon alfa-2b biosimilar developed by BioPartners. Reference product Intron A and PegIntron (Merck).
Brands by market: Alpheon (EU, interferon alfa-2a, refused) · Commercial partner or holder: BioPartners · Company profile
FDANot listed
EMAWithdrawn
MHRANot listed
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Not yet approved in any of the 7 markets
Connections
About Alpheon
Alpheon was an interferon alfa-2a biosimilar filed in Europe by BioPartners. The committee refused it in June 2006, one of the first biosimilar applications in Europe and the first to be refused, on the grounds that the comparison with the reference product was not sufficient.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Alpheon
European Medicines Agency and European CommissionWithdrawnBrand
Alpheon
Holder or applicant
BioPartners GmbH
Pathway
Centralised (Article 10(4))
Approved
not published
Application or permission
EMEA/H/C/000585
Withdrawn
date not published
Presentations
see SmPC
Remarks
Interferon alfa-2a biosimilar refused by the CHMP, opinion 28 June 2006.
Source
S017 (EMA) · checked Sep 2026
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Same developer, other molecules
Other biosimilars in the Atlas developed by BioPartners: Valtropin.
Chronology
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning interferon alfa-2b biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.